Why do firms struggle with mass tort analytics software?
Most software marketed as "mass tort software" is case management software. It is designed to organize cases a firm already has — not to surface developing torts, evaluate entry timing, or benchmark case economics. This category confusion explains why many plaintiff firms find their analytics stack gives them good operational visibility and poor strategic intelligence.
The category confusion that creates the problem
When a plaintiff firm searches for "mass tort software," most of the results are case management platforms. That is not what most firms asking the question actually need — or at least, it is not the whole answer.
Case management software is genuinely useful. Filevine, Litify, CasePeer, and similar platforms solve real operational problems: tracking which cases are in which stage, managing deadlines, organizing documents, and moving files through the firm's workflow. For a firm handling hundreds or thousands of mass tort cases, that infrastructure is not optional.
But case management software does not answer the questions that determine whether a firm builds a profitable mass tort practice or ends up as a late entrant competing for a shrinking claimant pool. Those questions are intelligence questions:
- What torts are developing that we are not yet tracking?
- How does this developing tort compare to others at a similar stage?
- What has the expected per-claim value been in structurally similar MDLs?
- How much time is there before the market for this claimant population saturates?
Buying a better case management tool does not answer those questions. Firms that do not separate the two categories end up with excellent operational infrastructure and a blind spot on strategic intelligence.
Why the market is structured this way
The dominance of case management in the "mass tort software" category is not accidental. Case management is a larger, more predictable, and more easily sold category than mass tort intelligence. Every firm with any case volume needs case management. The need for dedicated litigation analytics or early-warning intelligence is more concentrated in firms with active mass tort practices — a smaller subset of the total market.
As a result, the major legal technology vendors have invested heavily in case management and relatively lightly in intelligence. The analytics tools that do exist — Lex Machina, Pattern Data, Verus — were built primarily for defense firms or for specific analytics use cases (judicial analytics, verdicts research) rather than for the plaintiff firm mass tort evaluation workflow.
This has left a gap that most plaintiff firms are filling with a patchwork: court analytics tools, manual regulatory database monitoring, legal press subscriptions, and informal intelligence-sharing with co-counsel. The patchwork works, but it is slow, labor-intensive, and inconsistent across firms and even across practice groups within the same firm.
The five specific things firms cannot do with case management alone
1. Identify developing torts before filing activity peaks
Case management software shows you the cases you already have. It has no view into what is developing in the external world — regulatory adverse events, early state court filings, litigation funding activity, or media coverage patterns that precede MDL formation. By the time a tort appears in a firm's case management system, someone has already decided to pursue it. The question of whether to pursue it at all — and how early — is not answered by the case management layer.
2. Benchmark expected outcomes against comparable torts
How much has a structurally similar MDL produced per claimant? How long did the lifecycle run? What injury profiles were included in the settlement class versus excluded? These questions require structured historical data from comparable cases — data that lives in verdict databases, MDL settlement records, and structured legal research tools, not in a firm's internal case management history.
3. Evaluate total claimant population size
Mass tort economics depend on inventory potential. A product that caused harm to a concentrated population of a few thousand claimants produces different economics than one affecting millions. Estimating total affected population requires product sales data, adverse event reporting rates, and epidemiological modeling — none of which is present in a case management system.
4. Assess defendant litigation posture before committing
How a defendant has historically responded to mass tort litigation — whether they fight hard and litigate to verdict, or whether they move quickly toward global resolution — is a significant input into the expected timeline and economics of any new matter. This requires research into the defendant's prior litigation history across different jurisdictions and contexts. Again, not something case management software provides.
5. Track tort maturity across the lifecycle
Mass torts move through recognizable stages — early cluster filings, state court consolidations, MDL formation, bellwether trials, global settlement negotiations, and distribution. A firm's optimal entry point and expected return depend on where a given tort sits in that lifecycle. Case management software does not give you a view across torts; it gives you a view inside the cases you already have.
A pattern worth noting. The firms most likely to describe their analytics software as "not giving us what we need" are often firms that are using it well — but using it for the wrong job. Case management done well is not a substitute for intelligence done well. These are tools that need to coexist in the stack, not compete for the same budget line.
What analytics capability actually looks like when it works
Firms with functioning analytics capabilities for mass tort evaluation have typically built or acquired several things that most case management platforms do not provide:
| Capability | What it enables | How most firms get it today |
|---|---|---|
| Regulatory adverse event monitoring | Early product liability signals before first filings | Manual FDA/NHTSA database review, vendor tools |
| MDL and docket pattern tracking | Tort maturity assessment, entry timing | Lex Machina, Docket Alarm, CourtListener |
| Comparable MDL outcome benchmarking | Expected per-claim value, lifecycle duration | Pattern Data, Verus, internal research |
| Claimant population estimation | Total inventory potential assessment | Internal analysis, co-counsel intelligence-sharing |
| Defendant posture research | Settlement vs. litigation probability | Docket analytics, attorney network, prior experience |
The pattern is consistent: the most valuable capabilities are the ones that are least well-served by purpose-built commercial tools. Regulatory monitoring, population estimation, and early-stage tort identification are all areas where firms are still largely relying on manual processes or general-purpose tools.
The organizational problem, not just the technology problem
Technology gaps explain part of why firms struggle with mass tort analytics. But a significant portion of the problem is organizational.
Mass tort evaluation requires a combination of skills that do not sit cleanly in any one role: legal judgment about case merit, data analysis to evaluate filing patterns and comparable outcomes, medical or scientific literacy to evaluate product liability claims, and market awareness to assess competitive entry timing. In most firms, these capabilities are distributed across people who do not always work closely together — attorneys, paralegals, intake staff, and business development personnel all hold pieces of the picture.
Firms that have the strongest analytics capabilities have typically assigned someone with explicit responsibility for mass tort intelligence and given them the resources and access to do it properly. That organizational commitment matters at least as much as the software selection.
What to look for in an analytics platform
If a firm is actively evaluating analytics tools to address these gaps, a few questions help separate tools that are genuinely useful from those that primarily produce the appearance of analytics:
- What is the data lag? How quickly does the platform incorporate new filing activity, regulatory data, and case outcomes? Platforms that update weekly are materially different from those that update quarterly.
- Is the data source transparent? Platforms that cannot explain where their data comes from or how it is validated should be evaluated skeptically. Legitimate analytics tools are built on identifiable sources.
- Does it cover pre-filing signals? If a platform only tracks what has already been filed, it is useful for benchmarking but not for early-warning. Firms that want to move early in developing torts need pre-filing intelligence.
- How does it fit with what you already have? Analytics tools work best when they complement existing case management infrastructure rather than attempting to replace it. Platforms that try to do both often do neither particularly well.
Frequently asked questions
Why do plaintiff firms struggle with mass tort analytics software?
The core problem is a category confusion: most software marketed as "mass tort software" is actually case management software. It is designed to track and move cases that a firm already has — not to evaluate whether a developing tort is worth entering, surface early signals before filing activity reaches critical mass, or benchmark expected case economics against comparable MDLs. Firms that buy case management expecting analytics capability inevitably find that the questions they care most about — what is developing, how big is this tort, and when should we enter — are not answered by the tools they have.
What is the difference between mass tort case management and mass tort analytics?
Case management answers internal operational questions: what cases do we have, what are the next deadlines, where does each file stand in the workflow, and what documents need to be produced? Tools like Filevine, Litify, and CasePeer are designed for this. Mass tort analytics answers external intelligence questions: what is happening in the courts and regulatory databases, what outcomes have comparable torts produced, how much claimant inventory exists nationally, and where is a given tort in its lifecycle? These are fundamentally different functions, and building one does not produce the other.
Can firms build their own mass tort analytics capability internally?
Some large plaintiff firms have built internal intelligence teams and proprietary databases. The firms that do this well are typically those with the capital to staff it, the data science capacity to build analytical infrastructure, and enough historical case volume to generate meaningful internal benchmarks. For most firms, the cost of building this internally exceeds the cost of licensing an analytics platform — and the internal build often produces a tool that is already out of date by the time it is usable. The more practical path for most firms is to combine a dedicated analytics platform with the internal case experience the firm already has.
How does The Point by Caseworth address the analytics gap?
The Point by Caseworth is designed specifically for the intelligence and early-warning layer that most case management tools do not cover. Rather than organizing a firm's existing inventory, The Point focuses on what is developing in the external environment — regulatory signals, early filing clusters, adverse event patterns, and other leading indicators that precede the MDL formation stage. It is positioned as a complement to, not a replacement for, the case management software a firm already uses. Firms evaluating it can explore it at caseworth.io/the-point.
What data sources matter most for mass tort evaluation?
The most useful data sources for mass tort evaluation span several categories: federal court docket data for understanding MDL formation and maturity; regulatory adverse event databases (FDA MedWatch, NHTSA complaints, CPSC reports) for early product liability signals; structured settlement databases for benchmarking expected per-claim values; and public media and litigation press for reading narrative around emerging torts. The challenge is that each source has a different lag time and a different signal quality. Regulatory adverse events can surface months before first filings; MDL formation data is late but high-confidence; media coverage falls somewhere in between.
For informational and educational purposes only. This article is not legal advice. References to specific platforms reflect publicly available information as of June 2026 and are not endorsements. Firms evaluating legal technology should conduct their own diligence based on practice area, existing infrastructure, and business objectives.